Your Source for Venture Capital and Private Equity Financings

FogPharma Announces $178M Series D Financing

2022-11-21
CAMBRIDGE, MA, FogPharma, a biopharmaceutical company, announced a $178 Million Series D financing.
FogPharma, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered 'undruggable,' announced a $178 Million Series D financing.

The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, and PagsGroup, also participated.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading